The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care

Pharmacoepidemiology and Drug Safety
Luis Alberto García-RodríguezSaga Johansson

Abstract

To compare mortality and the incidence of hospitalization for myopathy, rhabdomyolysis, acute renal failure and acute liver injury in patients receiving rosuvastatin and those taking other statins. Patients prescribed a statin that they had not used before were selected from the UK General Practice Research Database (GPRD) and followed up from 1 April 2003 to 31 December 2005. We studied 10 289 patients on rosuvastatin and 117 102 taking other statins. No cases of myopathy, rhabdomyolysis or acute liver injury occurred among rosuvastatin users. In those taking statins other than rosuvastatin, the incidence of myopathy was 0.4 (95% confidence interval (CI): 0.1-0.9), of rhabdomyolysis was 0.4 (95%CI: 0.1-0.9) and of acute liver injury was 0.4 (95%CI: 0.2-1.0), per 10 000 person-years. Fourteen cases of acute renal failure were identified (two among rosuvastatin users and 12 among other statin users). Among current users, the relative risk (RR) of acute renal failure in rosuvastatin users compared with other statin users was 1.16 (95%CI: 0.15-9.03).We identified 3232 deaths during the study period (173 in the rosuvastatin-treated group and 3059 in the other statin group). The RR of death associated with current use of rosuvastati...Continue Reading

References

Jun 27, 1998·British Journal of Clinical Pharmacology·L A García Rodríguez, S Pérez Gutthann
Aug 17, 1999·Archives of Internal Medicine·S D RossD Luo
Apr 20, 2001·JAMA : the Journal of the American Medical Association·T P van StaaC Cooper
Aug 2, 2002·Current Opinion in Lipidology·Marc Evans, Alan Rees
Aug 21, 2002·Circulation·Richard C PasternakUNKNOWN National Heart, Lung and Blood Institute
Sep 7, 2002·Stroke; a Journal of Cerebral Circulation·Richard C PasternakUNKNOWN National Heart, Lung and Blood Institute
Dec 24, 2002·Pharmacotherapy·Corri Black, Hershel Jick
May 14, 2003·Pharmacotherapy·Susan S JickHershel Jick
Aug 9, 2003·Expert Opinion on Drug Safety·Michael H Davidson
Mar 25, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Naga Chalasani
Apr 13, 2005·Archives of Internal Medicine·Marco StuderHeiner C Bucher
May 27, 2005·Pharmacoepidemiology and Drug Safety·Mark Epstein, UNKNOWN International Society of Pharmacoepidemiology
Oct 21, 2005·British Journal of Clinical Pharmacology·T WalleyE Van Ganse
Apr 4, 2006·The American Journal of Cardiology·Malcolm Law, Alicja R Rudnicka
Apr 4, 2006·The American Journal of Cardiology·Mark J CzirakyMichael H Davidson
May 31, 2006·Pharmacoepidemiology and Drug Safety·Saga JohanssonAlexander M Walker
Jun 9, 2006·Pharmacoepidemiology and Drug Safety·W G GoettschR M C Herings
Jun 9, 2006·Pharmacoepidemiology and Drug Safety·Andrew T McAfeeAlexander M Walker

❮ Previous
Next ❯

Citations

Oct 5, 2011·Current Neurology and Neuroscience Reports·F L Mastaglia, M Needham
Mar 9, 2012·The New England Journal of Medicine·William S DavidE Tessa Hedley-Whyte
Jun 30, 2011·European Heart Journal·UNKNOWN European Association for Cardiovascular Prevention & RehabilitationUNKNOWN ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees
Sep 26, 2013·Current Opinion in Rheumatology·Payam Mohassel, Andrew L Mammen
Sep 10, 2010·Current Opinion in Rheumatology·Andrew L Mammen, Anthony A Amato
Aug 21, 2013·Indian Journal of Endocrinology and Metabolism·Debasish MajiKumar Gaurav
May 13, 2014·Molecular Aspects of Medicine·Huifen WangAlice H Lichtenstein
May 15, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Aaron J KatzPaul E Stang
Oct 10, 2012·Expert Opinion on Drug Safety·Guillermo Di Girolamo, Claudio González
Oct 18, 2011·Expert Opinion on Drug Safety·Peter P Toth, Thomas D Dayspring
Feb 5, 2009·Annals of Medicine·Dan AtarRichard Hobbs
Apr 22, 2009·Pharmacoepidemiology and Drug Safety·Nawab Qizilbash
Jan 13, 2012·Pharmacoepidemiology and Drug Safety·Ameet BakhaiCathy Emmas
Mar 23, 2013·Muscle & Nerve·Payam Mohassel, Andrew L Mammen
Jan 11, 2011·Journal of Vascular Surgery·Kosmas I ParaskevasFrank J Veith
Feb 11, 2015·Medicina clínica·Marcelo Alvarado CárdenasUNKNOWN en representación del Grupo para estudio de Autoinmunidad y Estatinas
Nov 20, 2016·Medicine·Marie HudsonUNKNOWN Canadian Scleroderma Research Group (CSRG)
Mar 14, 2018·Critical Reviews in Analytical Chemistry·Marilene Lopes ÂngeloMagali Benjamim de Araújo
May 7, 2010·The American Journal of Gastroenterology·Ted Bader
Feb 14, 2015·Muscle & Nerve·Jessica R Nance, Andrew L Mammen
Nov 26, 2010·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Pedro Plans-Rubió
Mar 12, 2011·Clinical Journal of the American Society of Nephrology : CJASN·Ali OlyaeiJose Rueda
Aug 24, 2017·Current Opinion in Rheumatology·Andrew L Mammen
Jan 17, 2015·Journal of Cellular and Molecular Medicine·Leonilde BonfratePiero Portincasa
Nov 26, 2011·Revista española de cardiología·Željko ReinerUNKNOWN Clinical Practice Guidelines Committee of the Spanish Society of Cardiology

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.